2025
Comparative analysis of PIK3CA mutation detection methods in the first-in-human phase 1/1b study of inavolisib.
Hilz S, Accordino M, Bedard P, Cervantes A, Gambardella V, Hamilton E, Italiano A, Jhaveri K, Juric D, Kalinsky K, Krop I, Oliveira M, Saura Manich C, Schmid P, Aimi J, Royer-Joo S, Schutzman J, Hutchinson K. Comparative analysis of PIK3CA mutation detection methods in the first-in-human phase 1/1b study of inavolisib. Journal Of Clinical Oncology 2025, 43: e13058-e13058. DOI: 10.1200/jco.2025.43.16_suppl.e13058.Peer-Reviewed Original ResearchMetastatic breast cancerHER2- metastatic breast cancerCtDNA testingNGS assaysTumor tissuesDetection concordanceTesting of tumor tissueFoundationOne Liquid CDxPIK3CA mutation testingFresh tumor tissueTissue-based testingBlood-based testOncogenic amino acid substitutionsBlood-based assayCatalytic subunit of PI3KSubunit of PI3KFoundation MedicineMutation detection methodsPIK3CA-mutationsTherapy regimenCtDNA sheddingAlpha catalytic subunitNG-TestReflex testAmino acid substitutions
2021
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types
Rolfo C, Drilon A, Hong D, McCoach C, Dowlati A, Lin JJ, Russo A, Schram AM, Liu SV, Nieva JJ, Nguyen T, Eshaghian S, Morse M, Gettinger S, Mobayed M, Goldberg S, Araujo-Mino E, Vidula N, Bardia A, Subramanian J, Sashital D, Stinchcombe T, Kiedrowski L, Price K, Gandara DR. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. British Journal Of Cancer 2021, 126: 514-520. PMID: 34480094, PMCID: PMC8811064, DOI: 10.1038/s41416-021-01536-1.Peer-Reviewed Original ResearchConceptsPlasma next-generation sequencingNTRK1 fusionsTumor typesAdvanced-stage solid tumorsNTRK fusion-positive tumorsTarget resistance mechanismsTissue-based testingHigh positive predictive valuePrimary tumor typeIdentification of patientsNon-invasive screening methodNext-generation sequencingFusion-positive tumorsPositive predictive valueDurable responsesPediatric patientsNTRK fusionsDrivers of carcinogenesisClinical dataTRK inhibitorsClinical practiceCtDNA analysisPredictive valueSolid tumorsOncogenic driversComplementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma
Zengin ZB, Weipert C, Salgia NJ, Dizman N, Hsu J, Meza L, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Chawla N, Philip EJ, Kiedrowski L, Maughan BL, Rathi N, Goel D, Choueiri TK, Agarwal N, Pal SK. Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clinical Cancer Research 2021, 27: 4807-4813. PMID: 34130999, DOI: 10.1158/1078-0432.ccr-21-0572.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaCell-free tumor DNARenal cell carcinomaGenomic profilingCell carcinomaTissue-based testingTumor DNA (ctDNA) assessmentClinical Laboratory Improvement AmendmentsActionable alterationsCtDNA profilingCtDNA assessmentPatientsTumor DNAUnique alterationsAlteration frequencyCarcinomaDNA assessmentBloodGreater temporal separationTissueAlterationsConcordancePrevious findingsMutationsConcordance analysis
2020
Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing
Zengin Z, Weipert C, Hsu J, Salgia N, Saam J, Choueiri T, Agarwal N, Pal S. Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing. Annals Of Oncology 2020, 31: s553-s554. DOI: 10.1016/j.annonc.2020.08.773.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply